Bridging Clinical Trial and Real-World Evidence in Retinal Diseases: Updated Strategies With Anti-VEGF Therapies

Please visit answersincme.com/BHT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara Stafford, MDCM, FRCPC and Gihane Zarifa, MD, CCFP, FCFP, MSc. In this activity, experts in family medicine and endocrinology discuss the role of oral glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in personalized type 2 diabetes (T2D) management. Upon completion of this activity, participants should be better able to: Discuss individualized, guideline-informed management strategies for T2D that address glycemic control, weight, and patient-specific factors; Differentiate key pharmacologic, administration, and tolerability characteristics of oral GLP-1 RAs to support patient counseling in T2D; and Interpret clinical evidence for approved and emerging oral GLP-1 RAs to inform their potential role in addressing gaps in T2D management.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.

Please visit answersincme.com/SJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jewel M. Kling, MD, MPH and Genevieve Neal-Perry, MD, PhD. In this activity, experts in menopause management discuss unmet therapeutic needs, emerging evidence for neurokinin (NK) receptor antagonists, and patient-focused strategies for managing menopause-associated vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Recognize unmet therapeutic needs among patients with menopause-associated VMS; Assess the evidence for nonhormonal therapies targeting NK receptors in the treatment of menopause-associated VMS; and Formulate patient-focused strategies for the optimal use of NK receptor antagonists for menopause-associated VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/BWG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses integrating clinical trial and real-world evidence into the use of newer-generation anti–vascular endothelial growth factor (VEGF) agents. Upon completion of this activity, participants should be better able to: Review the role of different types of data in informing management of retinal diseases; Assess clinical trial data and real-world evidence supporting the use of newer-generation anti-VEGF agents for retinal diseases; and Propose treatment plans for the management of retinal diseases based on clinical trial data and real-world evidence.

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

Please visit answersincme.com/ZYD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH. In this activity, an expert in dermatology discusses best practices to diagnose and manage bullous pemphigoid (BP). Upon completion of this activity, participants should be better able to: Review the process for diagnosing patients with BP; Assess the evidence for the use of biologics targeting type 2 inflammation in the treatment of BP; and Outline the clinical implications of the evidence for the treatment of BP with biologics targeting type 2 inflammation.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/860/103760795-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; Mike Sharma, MD, MSc; and Eddie Needham, MD, FAAFP. In this activity, experts in atrial fibrillation (AF) discuss evidence-based strategies to optimize stroke prevention, address anticoagulation gaps in clinical practice, and prepare for emerging approaches to anticoagulation. Upon completion of this activity, participants should be better able to: Apply evidence-based risk stratification tools and guidelines to address anticoagulation gaps in primary care patients with AF; Assess the clinical impact of suboptimal anticoagulation on AF stroke prevention; Evaluate emerging strategies for AF stroke prevention, including factor XI/XIa inhibitors; and Outline multidisciplinary, equity-focused care strategies incorporating social determinants to optimize AF stroke prevention in diverse populations.